10.06.2021 Views

The Indian Weekender, 11 June 2021

Weekly Kiwi-Indian publication printed and distributed free every Friday in Auckland, New Zealand

Weekly Kiwi-Indian publication printed and distributed free every Friday in Auckland, New Zealand

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

14<br />

INDIA<br />

Friday, <strong>June</strong> <strong>11</strong>, <strong>2021</strong> <strong>The</strong> <strong>Indian</strong> <strong>Weekender</strong><br />

NEWS in BRIEF<br />

Cheetah: <strong>The</strong> world's fastest cat is returning<br />

to India<br />

If all goes well,<br />

eight cheetahs<br />

- five males and<br />

three females - will<br />

make the 8,405km<br />

(5,222 miles) journey from South Africa to their new home in<br />

a sprawling national park in India in November. <strong>The</strong> world's<br />

fastest land animal will make a comeback in India, more than<br />

half a century after it became extinct in the country.<br />

"Finally we have the resources and the habitat to reintroduce<br />

the cat," says Yadvendradev Jhala, dean of the Wildlife Institute<br />

of India, and one of the experts tasked with the effort. This is<br />

the first time in the world, he says, when a large carnivore will<br />

be relocated from one continent to another for conservation.<br />

With their black spotted coats and teardrop marks, the<br />

cheetah is a sleek animal, racing across grasslands at speeds<br />

touching 70 miles (<strong>11</strong>2km) an hour to capture prey. <strong>The</strong> cat is<br />

also a remarkably athletic animal, braking, ducking and diving<br />

as it goes for the kill.<br />

<strong>The</strong> vast majority of the 7,000 cheetahs in the world are now<br />

found in South Africa, Namibia and Botswana. <strong>The</strong> endangered<br />

cat was reportedly last sighted in India in 1967-68, but their<br />

numbers had vastly dwindled by 1900.<br />

Coronavirus: <strong>The</strong> 'unknown' Covid-19<br />

deaths in rural India<br />

<strong>The</strong> second wave of Covid-19 ravaged India as hospitals<br />

and then crematoriums ran out of space.<br />

Families struggled to find beds, oxygen or even medicines<br />

to save their loved ones. While cities were first hit, the second<br />

wave soon reached rural parts of the country.<br />

Hundreds died due to poor or no access to good healthcare.<br />

Most of them were not even able to get a Covid test done.<br />

Now experts believe that the number of deaths in rural India<br />

is much higher than official statistics.<br />

India's cumulative Covid-19 vaccine<br />

coverage crosses 240 million-mark<br />

<strong>The</strong> number of Covid-19<br />

vaccine doses administered<br />

in the country has crossed 24<br />

crore, the Union Health Ministry<br />

said. <strong>The</strong> ministry said that in<br />

the 18-44 age group, 19,24,924<br />

beneficiaries received the first<br />

dose of vaccine and 86,450 got<br />

the second dose on Wednesday.<br />

So far, 3,38,08,845 people in the 18-44 age group have<br />

received the first dose across states and union territories and<br />

4,05,<strong>11</strong>4 have got the second dose.<br />

Bihar, Delhi, Gujarat, Haryana, Karnataka, Madhya Pradesh,<br />

Maharashtra, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh<br />

and West Bengal have administered the first dose to more<br />

than 10 lakh beneficiaries in the 18-44 age group each, the<br />

ministry said. <strong>The</strong> country has administered cumulatively<br />

24,24,79,167 vaccine doses, according to a provisional report<br />

at 7 pm on Wednesday.<br />

Covaxin effective in neutralising Delta, Beta<br />

variants of Covid-19: Study<br />

Researchers at Pune’s<br />

<strong>Indian</strong> Council of<br />

Medical Research-National<br />

Institute of Virology<br />

(ICMR-NIV) found that<br />

Bharat Biotech’s Covaxin<br />

is effective in neutralizing<br />

the Delta (B.1.617.2) and<br />

Beta (B.1.351) variants of SARS-CoV-2, which causes the<br />

coronavirus disease (Covid-19).<br />

<strong>The</strong> paper, which is yet to be peer-reviewed, is titled -<br />

“Neutralization against B.1.351 and B.1.617.2 with sera of<br />

COVID-19 recovered cases and vaccinees of BBV152”<br />

- and has been authored by <strong>Indian</strong> Council of Medical<br />

Research (ICMR), the ICMR-NIV and Bharat Biotech.<br />

“<strong>The</strong> study demonstrated that despite a reduction in<br />

neutralization titers with BBV152 vaccinees sera against<br />

B.1.351 and B.1.617.2, its neutralization potential is well<br />

established,” the study pointed out, claiming that the<br />

vaccine developed by the Hyderabad-based pharmaceutical<br />

company is effective against these two variants which<br />

caused widespread concern among doctors for its increased<br />

severity.<br />

VACCINATION<br />

is important to protect<br />

against a spreading variant first<br />

identified in India, Fauci says<br />

Dr. Anthony Fauci pleaded with the<br />

public Tuesday to get vaccinated,<br />

saying the Delta coronavirus<br />

variant -- the B.1.617.2 variant first<br />

identified in India -- accounts for more<br />

than 6% of the sequenced viruses in the<br />

United States.<br />

<strong>The</strong> variant's spread and dominance<br />

in the United Kingdom, which was first<br />

hit hard by the Alpha variant -- B.1.1.7 --<br />

could spell trouble for the United States if<br />

people don't get vaccinated, Fauci said in<br />

a White House Covid-19 briefing.<br />

"We cannot let that happen in the United<br />

States," Fauci said, adding it's "such a<br />

powerful argument" to get vaccinated.<br />

<strong>The</strong> Delta variant "may be associated<br />

with an increased disease severity, such<br />

as hospitalization risk, compared to (the<br />

Alpha variant, B.1.1.7)," Fauci said.<br />

<strong>The</strong> variant is susceptible to available<br />

two-dose vaccines from Pfizer and<br />

AstraZeneca, he said, but protection from<br />

these vaccines requires following a twodose<br />

schedule.<br />

"<strong>The</strong>re is reduced vaccine effectiveness<br />

in the one dose," said Fauci, who is<br />

the National Institute of Allergy and<br />

Infectious Diseases director. "Three<br />

weeks after one dose, both vaccines, the<br />

(AstraZeneca) and the Pfizer/BioNTech,<br />

were only 33% effective against<br />

symptomatic disease from Delta."<br />

<strong>The</strong>re is not yet a booster vaccine trial<br />

underway specific to the Delta variant,<br />

but variant-specific boosters may be on<br />

the horizon, Fauci said.<br />

A booster may focus on a specific<br />

variant, or the type a person was originally<br />

vaccinated against, he said.<br />

"We are approaching both of those, but<br />

the one thing that we are noticing that's<br />

important is that the higher your degree of<br />

immune response against the wild type,<br />

the greater the secondary coverage you<br />

have against a wide array of variants,"<br />

he said. "You can boost against the wild<br />

type, and still cover variants, including<br />

617."<br />

Vaccination numbers have<br />

plummeted since April<br />

Fauci's plea for Americans to get<br />

vaccinated against Covid-19 comes as<br />

vaccinations across the country have<br />

slowed, leaving unvaccinated Americans<br />

vulnerable to new variants and<br />

threatening the chances of reaching<br />

h e r d<br />

immunity.<br />

Over the last week, the US averaged<br />

more than 1.07 million Covid-19 vaccine<br />

shots administered per day -- well below<br />

the peak seven-day average of 3.38<br />

million shots per day reached on April<br />

13, according to data from the Centers for<br />

Disease Control and Prevention.<br />

Mississippi is the state with the<br />

lowest percentage of its population<br />

fully vaccinated -- 27.5% as of Monday,<br />

according to the CDC.<br />

<strong>The</strong> state fell from 128,841 doses<br />

administered during the week ending<br />

March 27 down to 24,374 doses in the<br />

week ending <strong>June</strong> 5.<br />

Alabama has the second-lowest<br />

percentage of fully vaccinated residents<br />

among all states -- 29.4% as of Monday,<br />

according to CDC data.<br />

<strong>The</strong> state fell from 44,397 doses<br />

administered April 8 down to 1,465 doses<br />

on Saturday, according to the Alabama<br />

Department of Public Health's Covid-19<br />

dashboard.<br />

Arkansas, Louisiana and Tennessee<br />

and Wyoming also had less than 33% of<br />

their populations fully vaccinated as of<br />

Monday.<br />

"I understand that in the short run<br />

we may get away with it, having slow<br />

vaccination rates," said Dr. Ashish Jha,<br />

dean of the Brown University School of<br />

Public Health.<br />

"But those people really are vulnerable<br />

– once we have more variants circulating<br />

in the United States -- to get reinfected<br />

and potentially get very sick."<br />

Even those who've already had<br />

coronavirus should get vaccinated<br />

because research shows immunity<br />

achieved through vaccination is better<br />

than immunity through previous<br />

infection, Fauci said.<br />

"We need to get vaccinated because<br />

vaccines are highly efficacious. <strong>The</strong>y are<br />

better than the traditional response you<br />

get from natural infection," Fauci<br />

said last month.<br />

Lab research shows<br />

those who previously<br />

had Covid-19 and<br />

received two doses of<br />

an mRNA vaccine "had<br />

interesting, increased<br />

protection against<br />

the variants of<br />

concern," he said.<br />

And those<br />

relying on their<br />

immunity from<br />

previous infection<br />

need to understand<br />

the danger of new<br />

variants, Jha said.<br />

"This is a bit of a misunderstanding that<br />

unfortunately a lot of people have ... this<br />

idea that if you've been infected that you<br />

have natural immunity that you don't need<br />

to get vaccinated," Jha said.<br />

"<strong>The</strong>re is no doubt about it in my mind<br />

that a vaccine-induced immunity is much<br />

more durable and is going to hold up<br />

much better against the variants."<br />

Right now, the three vaccines used<br />

in the US work well against known<br />

variants of concern. But as coronavirus<br />

keeps spreading and mutating among<br />

unvaccinated people, "there may be future<br />

variants for which we are not so lucky,"<br />

said emergency physician Dr. Megan<br />

Ranney, director of the Brown-Lifespan<br />

Center for Digital Health.<br />

Rare breakthrough infections<br />

have milder outcomes<br />

While the Moderna, Pfizer/BioNTech<br />

and Johnson & Johnson vaccines are<br />

highly effective at preventing severe<br />

Covid-19, they're not perfect at preventing<br />

infection. But even those who get infected<br />

down the road after getting vaccinated<br />

will likely be less miserable than if they<br />

hadn't gotten vaccinated at all.<br />

CDC data published research showing<br />

those who had rare "breakthrough"<br />

infections after one or two doses of<br />

vaccine had 40% less virus in their bodies<br />

and were 58% less likely to have a fever.<br />

<strong>The</strong>y also spent two fewer days in bed<br />

than unvaccinated Covid-19 patients,<br />

according to the study.<br />

"<strong>The</strong> only way to be protected is to be<br />

fully vaccinated," Jha said.<br />

For those taking the Pfizer/BioNTech<br />

or Moderna vaccines, "This is why<br />

everybody needs a second dose."<br />

Moderna says data on<br />

vaccines for 5-year-olds<br />

likely available in early fall<br />

Moderna anticipates it will have data<br />

on the Covid-19 vaccine for children as<br />

young as 5 in September or October.<br />

"I think it's going to be early fall just<br />

because we have to go down in age very<br />

slowly and carefully," Moderna CEO<br />

Stéphane Bancel said at an event Monday<br />

hosted on the social media platform<br />

Clubhouse.<br />

<strong>The</strong> Pfizer/BioNTech vaccine has<br />

already been approved for children as<br />

young as 12. Moderna said it is testing its<br />

vaccine on children as young as 6 months.<br />

Bancel said the process will take time<br />

as it determines the appropriate dosages<br />

for small children. "We anticipate data<br />

available in the September/October time<br />

frame," he said.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!